Related Experiment Video

Updated: Aug 7, 2026

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
14:45

Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency

Published on: August 6, 2014

Todralazine influence upon the mutagenicity of some direct- and indirect-acting mutagens

K Gasiorowski1, K Szyba, J Urban

  • 1Medical Academy, Department of Basic Medical Sciences, Wroclaw, Poland.

Mutation Research
|July 1, 1994
PubMed

Insights

Todralazine significantly reduced mutagenic activity in both direct and indirect mutagens. This antimutagenic effect was substantial, often exceeding 80% for certain mutagen types.

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • Mutagens pose risks to genetic integrity.
  • Understanding antimutagenic compounds is crucial for mitigating these risks.
  • Todralazine's potential antimutagenic properties warrant investigation.

Purpose of the Study:

  • To evaluate the antimutagenic efficacy of todralazine.
  • To determine the effect of todralazine on both direct and indirect mutagens.
  • To quantify the reduction in mutagenic activity.

Main Methods:

  • Assessing mutagenic activity of various mutagens.
  • Administering todralazine at different effective doses (ED50).
  • Quantifying the decrease in mutagenic activity post-todralazine treatment.

Main Results:

  • Todralazine demonstrated a significant decrease in mutagenic activity.
  • The reduction was observed for both direct-acting and indirect-acting mutagens.
  • In several cases, todralazine reduced mutagenicity by over 80%.

Conclusions:

  • Todralazine exhibits potent antimutagenic properties.
  • It effectively counteracts mutagenicity induced by a range of chemical agents.
  • Todralazine represents a promising agent for reducing chemically induced genetic damage.

More Related Videos

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs08:13

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Published on: December 27, 2016

The Lambda Select cII Mutation Detection System07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).